An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples

Journal of Steroid Biochemistry and Molecular Biology

Volumn 109, Issue 1-2, 2008, Pages 90-95

  Geisler, Jürgen ^a,b   Ekse, Dagfinn ^b   Helle, Hildegunn ^b   Duong, Nhat Kim ^b   Lønning, Per Eystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aromatase inhibitors; Estradiol; Estrogen measurements; Estrone; Estrone sulfate; Radioimmunoassay

Indexed keywords

ESTRADIOL; ESTRONE; ESTRONE SULFATE;

ARTICLE; CHROMATOGRAPHY; FEMALE; HUMAN; HYDROLYSIS; POSTMENOPAUSE; PROTEIN PURIFICATION; RADIOIMMUNOASSAY;

AROMATASE INHIBITORS; BLOOD CHEMICAL ANALYSIS; BREAST NEOPLASMS; ESTRADIOL; ESTRONE; HUMANS; POSTMENOPAUSE; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY;

EID: 40849123942     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.12.011     Document Type: Article

References (27)

1. Raisz L.G. Estrogen and bone: new pieces to the puzzle. Nat. Med. 2 (1996) 1077-1078
2. Simpson E.R. Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 86 (2003) 225-230
3. Toniolo P.G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., Strax P., and Pasternack B.S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 87 (1995) 190-197
4. Thomas H.V., Key T.J., Allen D.S., Moore J.W., Dowsett M., Fentiman I.S., and Wang D.Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br. J. Cancer 76 (1997) 401-405
5. Berrino F., Muti P., Micheli A., Bolelli G., Krogh V., Sciajno R., Pisani P., Panico S., and Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. 88 (1996) 291-296
6. Dorgan J.F., Longcope C., Stanczyk F.Z., Stephenson H.E., and Hoover R.N. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 91 (1999) 380-381
7. Geisler J., and Lonning P.E. Aromatase inhibition: translation into a successful therapeutic approach. Clin. Cancer Res. 11 (2005) 2809-2821
8. Bonneterre J., Buzdar A., Nabholtz J.M., Robertson J.F., Thurlimann B., von Euler M., Sahmoud T., Webster A., and Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 (2001) 2247-2258
9. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A., and Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19 (2001) 2596-2606
10. Paridaens R., Dirix L., Lohrisch C., Beex L., Nooij M., Cameron D., Biganzoli L., Cufer T., Duchateau L., Hamilton A., Lobelle J.P., and Piccart M. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol. 14 (2003) 1391-1398
11. Baum M., Buzdar A.U., Cuzick J., Forbes J., Houghton J., Klijn J.G.M., Sahmoud T., and Grp A.T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
12. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M., Castiglione M., Dongsheng T., Shepherd L.E., Pritchard K., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Therasse P., Palmer M.J., and Pater J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early-stage breast cancer. N. Engl. J. Med. 349 (2003) 1793-1802
13. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., Smith I., Wardley A., Price K.N., and Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
14. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., and Bliss J.M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
15. Lønning P.E. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs Aging 19 (2002) 277-298
16. Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Caroti C., Farris A., Cruciani G., Villa E., Schieppati G., and Mustacchi G. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an italian cooperative study. J. Clin. Oncol. 19 (2001) 4209-4215
17. Lønning P.E. Aromatase inhibitors in breast cancer. Endocr. Relat. Cancer 11 (2004) 179-189
18. Lonning P.E., Geisler J., Johannessen D.C., and Ekse D. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. J. Steroid Biochem. Mol. Biol. 61 (1997) 255-260
19. Santen R., Demers L., Ohorodnik S.K., Settlage J., Langecker P., Blanchett D., Goss P.E., and Wang S. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72 (2007) 666-671
20. Dowsett M., Jones A., Johnston S.R.D., Jacobs S., Trunet P., and Smith I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin. Cancer Res. 1 (1995) 1511-1515
21. Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P., Kormeset P.O., and Lonning P.E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer 74 (1996) 1286-1291
22. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol. 20 (2002) 751-757
23. Geisler J., King N., Anker G., Ornati G., Di Salle E., Lonning P.E., and Dowsett M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. 4 (1998) 2089-2093
24. Santen R.J., Santner S., Davis B., Veldhuis J., Samojlik E., and Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab. 47 (1978) 1257-1265
25. Lønning P.E., and Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35 (1988) 685-710
26. Lonning P.E., and Ekse D. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 55 (1995) 409-412
27. Koch D.D., and Peters T. Selection and evaluation of methods. In: Burtis C.A., and Ashwood E.R. (Eds). Fundamentals of Clinical Biochemistry (1996), Saunders, Philadelphia, PA, USA 170-181